• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket

    10/16/23 8:47:12 AM ET
    $AMAM
    $APH
    $AQB
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Electrical Products
    Technology
    Get the next $AMAM alert in real time by email

    Gainers

    LQR House Inc. (NASDAQ:LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves.

    Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares rose 84.4% to $0.8853 in pre-market trading after jumping 45% on Friday.

    MingZhu Logistics Holdings Limited (NASDAQ:YGMZ) shares gained 62.8% to $0.7766 in pre-market trading after gaining more than 10% on Friday.

    PCTEL, Inc. (NASDAQ:PCTI) shares climbed 47.4% to $6.87 in pre-market trading. On Friday, Amphenol Corp (NYSE:APH) inked a deal to acquire PCTEL for around$139.7 million.

    RedHill Biopharma Ltd. (NASDAQ:RDHL) shares rose 43.8% to $0.46 in pre-market trading after falling 14% on Friday.

    Secoo Holding Limited (NASDAQ:SECO) rose 37.7% to $0.8810 in pre-market trading after declining 37% on Friday.

    ESSA Pharma Inc. (NASDAQ:EPIX) gained 32.1% to $3.62 in pre-market trading.

    Almacenes Éxito S.A. (NYSE:EXTO) shares rose 31.6% to $6.61 in pre-market trading.

    ContraFect Corporation (NASDAQ:CFRX) shares jumped 30% to $0.7398 in pre-market trading after the company reported FDA clearance of CF-370 IND application to proceed with Phase 1 clinical study.

    Ambrx Biopharma Inc. (NASDAQ:AMAM) rose 24.9% to $17.55 in pre-market trading.

    Losers

    Sigma Additive Solutions, Inc. (NASDAQ:SASI) dipped 24.8% to $4.47 in pre-market trading after jumping 140% on Friday.

    Shift Technologies, Inc. (NASDAQ:SFT) shares fell 24.1% to $0.1199 in pre-market trading. Maruthi J. D. Venkata reported a 4.8% stake in Shift Technologies as of Oct 12, 2023 versus an 11.5% stake reported as of March 14, 2023.

    ParaZero Technologies Ltd. (NASDAQ:PRZO) shares fell 19.1% to $2.67 in pre-market trading, after jumping 55% on Friday.

    Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares fell 19.1% to $0.6060 in pre-market trading after jumping around 111% on Friday.

    AquaBounty Technologies, Inc. (NASDAQ:AQB) fell 15.8% to $3.45 in pre-market trading.

    Versus Systems Inc. (NASDAQ:VS) fell 14.5% to $0.20 in pre-market trading. Versus Systems reported pricing of $3.0 million public offering.

    FaZe Holdings Inc. (NASDAQ:FAZE) shares fell 12.5% to $0.2039 in pre-market trading after jumping around 25% on Friday.

    UTime Limited (NASDAQ:WTO) shares fell 10.7% to $0.2810 in pre-market trading, after gaining over 7% on Friday.

    Manchester United plc (NYSE:MANU) shares fell 10.6% to $17.85 in pre-market trading.

    BioNTech SE (NASDAQ:BNTX) fell 6% to $97.35 in pre-market after the company's partner, Pfizer, cut its COVID-19 vaccine and therapy sales outlook.

    Now Read This: Why The Fear Level Among US Investors Is Growing

    Get the next $AMAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMAM
    $APH
    $AQB
    $BNTX

    CompanyDatePrice TargetRatingAnalyst
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Amphenol Corporation
    $APH
    1/12/2026$156.00Equal Weight → Overweight
    Barclays
    Amphenol Corporation
    $APH
    10/15/2025$150.00Neutral → Buy
    BofA Securities
    Amphenol Corporation
    $APH
    10/8/2025$120.00Equal Weight
    Barclays
    BioNTech SE
    $BNTX
    6/5/2025$134.00 → $145.00Buy
    H.C. Wainwright
    BioNTech SE
    $BNTX
    5/29/2025$110.00Neutral
    Goldman
    Amphenol Corporation
    $APH
    4/24/2025$85.00Equal Weight → Overweight
    Fox Advisors
    More analyst ratings

    $AMAM
    $APH
    $AQB
    $BNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amphenol Announces Pricing of Euro-Denominated Senior Notes Offering

    Amphenol Corporation (NYSE:APH) (the "Company") announced today the pricing of an offering of €500 million aggregate principal amount of senior notes due 2031 (the "Notes") to be issued by its wholly owned subsidiary Amphenol Technologies Holding GmbH ("Amphenol Technologies"), a German limited liability company (Gesellschaft mit beschränkter Haftung). The Notes will be guaranteed by the Company and will have an interest rate of 3.625% per annum. The closing of the offering of the Notes (the "Notes Offering") is expected to occur on March 30, 2026, subject to the satisfaction of customary closing conditions. Amphenol Technologies intends to use the net proceeds from the Notes Offering to

    3/24/26 4:15:00 PM ET
    $APH
    Electrical Products
    Technology

    ParaZero Technologies Ltd. Announces Closing of $4 Million Registered Direct Offering

    TEL AVIV, ISRAEL, March 24, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "Company"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale of approximately $4 million of ordinary shares and pre-funded warrants at a price of $0.75 per ordinary share. The offering consisted of the sale of 5,333,333 ordinary shares (or pre-funded warrants) at a public offering price of $0.75 per ordinary share (or $0.74999 for each pre-funded warrant, which is

    3/24/26 10:20:54 AM ET
    $PRZO
    Military/Government/Technical
    Industrials

    BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

    Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer immunotherapies, and their combinationsData updates for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, from three clinical trials conducted in China further strengthen the evidence supporting its previously observed efficacy and safety profile in lung cancerResults of stage 1 from the global Phase 3 PRESERVE-003 clinical trial of gotistobart showed clinically meaningful survival outcomes and antitumor activity compared to the current standard of care in second-line or later th

    3/24/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $APH
    $AQB
    $BNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Livingston Robert bought $1,285,080 worth of shares (10,000 units at $128.51), increasing direct ownership by 8% to 135,720 units (SEC Form 4)

    4 - AMPHENOL CORP /DE/ (0000820313) (Issuer)

    2/6/26 4:01:08 PM ET
    $APH
    Electrical Products
    Technology

    Director Yorke Justin W bought $9,889 worth of shares (12,400 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/31/25 5:06:27 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ng George K bought $69,542 worth of shares (87,200 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/29/25 5:05:00 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $APH
    $AQB
    $BNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech upgraded by Goldman with a new price target

    Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00

    1/16/26 8:19:35 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amphenol upgraded by Barclays with a new price target

    Barclays upgraded Amphenol from Equal Weight to Overweight and set a new price target of $156.00

    1/12/26 7:37:33 AM ET
    $APH
    Electrical Products
    Technology

    $AMAM
    $APH
    $AQB
    $BNTX
    SEC Filings

    View All

    Amphenol Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AMPHENOL CORP /DE/ (0000820313) (Filer)

    3/24/26 5:27:22 PM ET
    $APH
    Electrical Products
    Technology

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    3/24/26 5:09:47 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by ParaZero Technologies Ltd.

    424B5 - ParaZero Technologies Ltd. (0001916241) (Filer)

    3/24/26 7:20:30 AM ET
    $PRZO
    Military/Government/Technical
    Industrials

    $AMAM
    $APH
    $AQB
    $BNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bell Roger

    3 - Manchester United plc (0001549107) (Issuer)

    3/24/26 10:49:18 AM ET
    $MANU
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 3 filed by new insider Cao Honggang

    3 - UTime Ltd (0001789299) (Issuer)

    3/24/26 7:31:06 AM ET
    $WTO
    Consumer Electronics/Appliances
    Technology

    SEC Form 3 filed by new insider Wang Yanzhi

    3 - UTime Ltd (0001789299) (Issuer)

    3/24/26 7:24:34 AM ET
    $WTO
    Consumer Electronics/Appliances
    Technology

    $AMAM
    $APH
    $AQB
    $BNTX
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Military UAV Sector Forecast to Surpass $40+ Billion as Modern Warfare Evolves

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense and military operations, reshaping strategies from reconnaissance to precision strike capabilities. Military drones offer armed forces enhanced situational awareness, reduced risk to personnel, and cost-efficient mission profiles across surveillance, target acquisition, logistics, and electronic warfare. As autonomous systems incorporating artificial intelligence and advanced sensor suites continue to mature, they are increasingly integral to networked battlefield operations and force multiplie

    2/19/26 8:30:00 AM ET
    $NOC
    $PRZO
    $UAVS
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical
    Aerospace

    Amphenol Announces Board Succession Plan

    Amphenol Corporation (NYSE:APH) today announced that the Board of Directors has appointed R. Adam Norwitt, currently serving as President and Chief Executive Officer, to the additional role of Chairman of the Board, effective on the date of the Company's 2026 Annual Meeting of Stockholders, which is expected to be in May 2026. After more than five decades with Amphenol, including serving as President from 1987 to 2006, Chief Executive Officer from 1996 to 2008 and as Chairman of the Board since 1997, Martin H. Loeffler intends to retire from the Board also effective in May. As part of this leadership transition, David P. Falck, who has served as a Director since 2013 and Presiding Director

    2/4/26 4:44:00 PM ET
    $APH
    Electrical Products
    Technology

    $AMAM
    $APH
    $AQB
    $BNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LQR House Inc.

    SC 13D/A - LQR House Inc. (0001843165) (Subject)

    11/25/24 4:41:10 PM ET
    $LQR
    Beverages (Production/Distribution)
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 7:32:27 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Versus Systems Inc.

    SC 13G/A - Versus Systems Inc. (0001701963) (Subject)

    11/14/24 7:30:32 PM ET
    $VS
    EDP Services
    Technology

    $AMAM
    $APH
    $AQB
    $BNTX
    Financials

    Live finance-specific insights

    View All

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

    MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will

    2/24/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AI and Electronic Warfare Are Rewriting the Rules of Modern Defense

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The Department of Defense's total IT budget for fiscal 2026 reached $66 billion, a $1.8 billion increase from 2025, with the Army boosting AI spending by 38.3% and the Air Force increasing force application funding by 143.8%[1]. Congress backed the shift with an $839 billion defense spending bill that allocated $7.6 billion for 47 F-35 Joint Strike Fighters and $474 million in additional funding for the EA-37B Compass Call electronic warfare aircraft[2]. VisionWave Holdings (NASDAQ:VWAV), Kratos Defense & Security Solutions (NASDAQ:KTOS), ParaZero Technologies (NASDAQ:PRZO), Innoviz Technologies (NASDAQ:INVZ),

    2/17/26 10:25:03 AM ET
    $BBAI
    $INVZ
    $KTOS
    Computer Software: Prepackaged Software
    Technology
    Auto Parts:O.E.M.
    Consumer Discretionary